Ľubomíra Fábryová, Pavol Tisoň
The aim of the prospective, observational study under real-world conditions in Slovak clinical practice in type 2 diabetic patients inadequately controlled on metformin monotherapy was to evaluate the effect of 6 months of combined therapy (metformin and vildagliptin) on comprehensive cardiometabolic management. After 6 months of combined therapy with metformin and vildagliptin we observed a statistically significant reduction in HbA1c of 1.34 % to 7.04 % (p < 0.001), a statistically significant reduction in fasting and postprandial glucose levels, increased proportion of patients achieving HbA1c < 6.5 % (23 %) and < 7.0 % (44 %), respectively. We observed a statistically significant reduction in HbA1c in all groups (males vs females, younger vs elderly, BMI < 30 vs. > 30, HbA1c ≤ 8% vs. HbA1c 8-10 % vs. HbA1c > 10%). Blood pressure values were stable throughout the study, approximately 50 % of patients had blood pressure < 140/90 mmHg. During the 6-month follow-up there was a statistically significant decrease in total cholesterol, LDL-C, TG. Also, there was a statistically significant change in AIP with a shift to less atherogenic lipoprotein phenotype. The study has demonstrated that the combination of vildagliptin and metformin leads to improvement in cardiometabolic control with minimum number of non-serious adverse events.